BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Senhwa Advances CX-5461 into NCI-Sponsored Trial for MYC-Aberrant Lymphoma

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

August 08, 2025 | News

Astria Licenses HAE Drug Navenibart to Japan’s Kaken in $32M+ Deal

-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties -- -- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart...

August 08, 2025 | News

Fapon Biopharma Enrolls First Patient in China Phase I Trial of Novel Immunotherapy FP008 for Solid Tumors

Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollmen...

August 06, 2025 | News

iNtRON Bio Unveils World-First Dual-Action Engineered Phage Targeting Colorectal Cancer-Causing Bacteria

Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeut...

August 06, 2025 | News

METiS Technologies Secures RMB 400 Million in Series D Funding to Advance AI-Powered Nanodelivery and Accelerate CGT Innovation

METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB 400 million Series...

August 05, 2025 | News

WuXi XDC’s New DP3 Facility Achieves GMP Release, Boosting Global Bioconjugate Manufacturing Capacity

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...

August 05, 2025 | News

Energenesis Completes Phase I Trial of ENERGI-F705PD, a Novel Oral Therapy for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pha...

August 04, 2025 | News

Atombeat and BioDuro Unite to Launch AI-Powered Platform for Next-Gen Peptide Drug Discovery

Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organizatio...

August 04, 2025 | News

Atombeat and BioDuro Unite to Launch AI-Powered Platform for Next-Gen Peptide Drug Discovery

Atombeat Inc., a leading force in AI for drug discovery, and BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organizatio...

August 04, 2025 | News

Everest Medicines Invests US$30.9 Million in I-Mab to Advance Next-Gen Immuno-Oncology Therapies

- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares alread...

August 04, 2025 | News

Mabwell’s CDH17-Targeting ADC 7MW4911 Receives IND Clearance in China and U.S.

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug ...

August 04, 2025 | News

Quanterix Launches First-to-Market p‑Tau 205 and 212 Assays, Expanding Alzheimer’s Biomarker Portfolio

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, announced the first to market, com...

August 01, 2025 | News

Leo Cancer Care’s Marie® Secures FDA 510(k) Clearance, Pioneering Upright Particle Therapy in the U.S.

Leo Cancer Care, a leader in upright radiotherapy solutions, announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. F...

July 31, 2025 | News

XellSmart Achieves World-First Patient Dosing in Pioneering iPSC-Derived Cell Therapy Trial for Spinal Cord Injury

XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved regis...

July 30, 2025 | News

Stay Connected